Explore

Trendline Trendline
DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke

DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke

DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke
Trendline Trendline
Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission

Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission

Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission
Trendline Trendline
Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD
Trendline Trendline
Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway
Trendline Trendline
SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions

SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions

SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy
Trendline Trendline
ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment

FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment

FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035

North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035

North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035